Anifrolumab Early Access Program - AMANA

Study identifier:D3461R00027

ClinicalTrials.gov identifier:NCT04750057

EudraCT identifier:N/A

CTIS identifier:N/A

Other

Official Title

An Early Access Program for Anifrolumab Treatment in Adult Patients with Active Systemic Lupus Erythematosus - AMANA

Medical condition

Systemic Lupus Erythematosus

Phase

N/A

Healthy volunteers

No

Study drug

Anifrolumab

Sex

All

Actual Enrollment

0

Study type

Expanded Access

Age

18 Years +

Date

Study Start Date: -
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Apr 2021 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Clinigen

Inclusion and exclusion criteria